How effective is rasagiline? Have the therapeutic effects been verified?

Rasagiline is a monoamine oxidase type B (MAO-B) inhibitor, which is widely used in the treatment of Parkinson's disease . It has good clinical value, especially for symptom control in early and middle-late stage patients. Its mechanism of action is to selectively inhibit MAO-B enzyme activity in the brain, thereby reducing the degradation of dopamine, increasing the concentration of dopamine in the synaptic gap, and improving Parkinson's symptoms such as motor dysfunction. Rasagiline has shown good efficacy as a single agent or in combination with levodopa, and its therapeutic effect has been confirmed by a number of large international clinical studies.

In patients with early-stage Parkinson's disease, rasagiline can be used as a single treatment to effectively delay the progression of motor symptoms and improve the patient's quality of life to a certain extent. When the disease develops to the middle and late stages, especially when patients experience movement fluctuations or "switching phenomenon", rasagiline, as an auxiliary medication to levodopa, can extend the duration of the "on phase", reduce the frequency of the "off phase", and improve the ability to perform daily activities. Long-term use has also been proven to be well tolerated, with fewer side effects and higher safety.

In addition, some studies have pointed out that rasagiline may also have potential neuroprotective effects. Although it has not yet been completely determined, this direction has received widespread attention. It may also have a positive impact on cognitive function and emotional state, especially in the symptoms of anxiety and depression often associated with Parkinson's disease.

Overall, the efficacy of rasagiline has been widely recognized by the international neurological community and has been included in the Parkinson's treatment guidelines in many countries. Whether used as initial treatment or in combination with other anti-Parkinson drugs, rasagiline can exert stable and reliable therapeutic effects. Standard use by patients under the guidance of professional physicians is expected to delay disease progression and improve quality of life. It is one of the important drug options in the treatment of Parkinson's disease.

Reference materials:https://www.azilect.com/